Status:
UNKNOWN
Differences in Immune Response Among HIV-1-infected Individuals With Previous or Current COVID-19 (CoVIHDis).
Lead Sponsor:
Asociacion para el Estudio de las Enfermedades Infecciosas
Conditions:
Covid19
Immune Suppression
Eligibility:
All Genders
18-85 years
Brief Summary
People living with HIV could have different susceptibility and outcome to the SARS CoV-2 infection. The risk of SARS CoV-2 infection in this population could be no related to HIV infection, immunodepr...
Detailed Description
Since March 2020, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has affected almost five million people in 168 countries on five continents, with more than 300.000 deaths (...
Eligibility Criteria
Inclusion
- adult (\>18 year-old), confirmed HIV-1-infection, and provide written informed consent, with previous SARS CoV-2 infection as demonstrated by clinical and a positive PCR (cases) or no previous compatible symptoms and no diagnosis of SARS-CoV-2 infection (controls, classified according to serological determination)
Exclusion
- unable to provide a written informed consent.
- immunological alterations (chronic intake of corticoid or immunosuppresants)
Key Trial Info
Start Date :
January 10 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 30 2023
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04526977
Start Date
January 10 2021
End Date
March 30 2023
Last Update
October 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Ramon y Cajal
Madrid, Spain, 28034